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ABSTRACT  
While Norway has many outstanding health registries that are used as a foundation for surveillance, quality 
control and epidemiologic research, it was recognized that a knowledge gap existed regarding the preva-
lence, incidence, and quality of health care delivery for cardiovascular diseases (CVD) which remains the 
primary cause of death in the country. Given broad agreement for the need for a registry by patient orga-
nizations, research environments and health authorities, the Norwegian Parliament decided to establish the 
Norwegian Cardiovascular Disease Registry (NCVDR) in March 2010 and then adopted new regulations in 
December 2011 which established the NCVDR. The registry consists of a core registry housed and main-
tained by the Norwegian Institute of Public Health (NIPH) that is supplemented with information from the 
medical quality registries housed and maintained by the hospital trusts. Given the burden of CVD among 
patients with diabetes and the unique challenges of medical care for CVD patients with diabetes, the regis-
tries also provides a new opportunity to advance diabetes research in Norway. 
 
 
INTRODUCTION AND DIABETES RESEARCH 
POTENTIAL OF THE NORWEGIAN CVD 
REGISTRY 
 
While there is evidence of declining mortality for acute 
myocardial infarction (1), CVD remains the leading 
cause of mortality in Norway (1,2). Further, there are 
concerns that the declining trend in CVD mortality 
may not be sustainable, reflective of subpopulations, 
or of disease burden. For example, there is evidence of 
increasing obesity and diabetes prevalence rates (3), 
and of an increasing incidence of acute myocardial 
infarction (MI) in women in Tromsø (4). Further, 
hospitalization rates for CVD do not reflect the same 
downward trend as that observed for CVD mortality 
(5), and hospitalizations for acute MI for those over 79 
years of age have not been declining (6). 
 While the burden of diabetes in Norway is not 
known, an estimated 3-5% of the Norwegian population 
has diabetes mellitus with prevalence peaking at 11-
12% for those 80-89 years of age (3,7-9). Diabetes 
mellitus is associated with a two- to four-fold increased 
risk of cardiovascular diseases including coronary 
heart disease, stroke, atrial fibrillation and flutter, and 
left ventricular hypertrophy (10-13). Both type 1 and 
type 2 diabetes mellitus are associated with excess 
CVD risks (14), and approximately 2/3rds of diabetic 
patients suffer from cardiovascular disease (15-19), 
posing unique challenges in the treatment and manage-
ment of patients. 
 A priority research arena is to elucidate best prac-
tice for the integrated care of patients with diabetes, 
particularly for those with cardiovascular complica-
tions. Data sources in Norway could provide an oppor-
tunity to advance this arena of research in which large 
population-based registries with comprehensive data 
on clinical management and outcomes could provide 
an opportunity to make meaningful contributions to 
the literature. An example of a research arena requi-
ring further investigation is the extent to which CVD 
complications among diabetic patients is related to the 
degree of glycemic control (20). The efficacy of glyce-
mic control interventions has not been observed for all 
CVD sequelae (21) and there is considerable uncer-
tainty regarding the nature of the glycemic control and 
CVD dose-response relationship (22-24). Further, dia-
betes represents a challenge to health care practitioners 
and patients alike in that intensive efforts to control 
hyperglycemia may potentially introduce competing 
risks. The Action to Control Cardiovascular Risk in 
Diabetes Study found increased mortality and no signi-
ficant reduction in cardiovascular disease events in the 
intensive intervention group (24). Research findings, 
thus far, have led to recommendations against overly 
strict glycemic control (25). 
 Another example of research promoting improved 
health care delivery for patients with diabetes was the 
finding of a nearly 4-fold excess risk of CVD observed 
among diabetic patients with prehypertension (systolic 
blood pressure of 120-139 mmHg and/or a diastolic 
blood pressure of 80-89 mmHg) (26) which has led to 
new recommendations for blood pressure control 
among diabetic patients. Another important research 
arena is the exploration of potential differences in drug 
efficacy in patients with and without diabetes (27-29). 
Finally, the extensive variability in the continuum of 
the diabetic condition needs to be considered in the 
evaluation of primary and secondary intervention app-
roaches (30). The above mentioned illustrations provide 
a few examples regarding the need for ongoing clinical 
epidemiological research for identifying best practices 
in the treatment of patients with diabetes. 
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BACKGROUND ON THE NORWEGIAN 
CARDIOVASCULAR DISEASE REGISTRY 
(NCVDR) AND LEGAL MANDATE 
 
The advantages of epidemiological research in Norway 
is well known given our national health care system, 
registries, and ability to link between data sources based 
upon the unique identification number of individuals. 
The formation of the Norwegian Cardiovascular 
Disease Registry (NCVDR) extends these epidemiolo-
gical research opportunities to cardiovascular diseases. 
Given broad agreement for the need for a registry by 
patient organizations, research environments and health 
authorities, the Norwegian Parliament decided to 
establish the Norwegian CVD Registry in March 2010 
and formally adopted new regulations on December 
16, 2011 which established the Registry with data 
collection commencing in January 2012 (31,32). In 
accordance with the statutory authority of the Health 
Register Law Act §8, the legislation established the 
NCVDR as a nationwide registry in which personal 
identification of patients can be collected without the 
requirement for informed consent from those regis-
tered in order to meet the goals of the registry; the 
legislation expanded the Norwegian Institute of Public 
Health’s (NIPH) disease surveillance mandate. The 
NIPH has data management responsibility and judicial 
responsibility for safeguarding patient privacy and 
confidentiality of patient information for the registry in 
accordance with applicable laws and regulations 
(32,33). Further, identifying information on individu-
als is removed from files used for analyses once a 
unique number is assigned to each person. This unique 
number enables researchers to generate health statistics 
without concern of duplicate enumeration of CVD 
events and makes it possible to track the same patient 
over time and from hospital to hospital. 
 The NCVDR consists of a core registry housed and 
maintained by the Bergen Division of the NIPH. A 
collaborative agreement is being finalized between 
NIPH and St. Olav's Hospital Trust to formalize the 
inclusion of clinical information collected by the medi-
cal quality registries, such as the Norwegian Myocar-
dial Infarct Registry (34) and the Norwegian Stroke 
Registry (35). The inclusion of data from the medical 
quality registries will provide details regarding the 
variable manifestations of cardiovascular disease, risk 
factors, co-morbidities, treatment and their results. In 
the future, it is anticipated that the NCVDR will also 
include information collected by primary care physi-
cians, which would provide additional information for 
CVD patients with diabetes, such as glycemic control. 
 
 
OBJECTIVES 
 
There are four primary objectives of the NCVDR: 
1. to provide comprehensive data regarding the inci-
dence and prevalence of CVD; 
2. to evaluate the prognosis of patients by relevant 
diagnostic categories and treatment modalities; 
3. to provide a means of supporting basic clinical 
research to enhance the quality of health care 
delivery; 
4. to provide evidence-based knowledge for primary 
and secondary prevention and health care planning. 
 
 
ABOUT THE REGISTRY AND 
COLLABORATIONS BETWEEN NIPH AND THE 
HOSPITAL TRUSTS 
 
The NCVDR is based upon the collaborative organiza-
tional model, which has been described in the report 
“Good Health Registries – Better Health” (36), in which 
the government seeks to register information from a 
variety of sources for important diseases and medical 
conditions for improving disease surveillance and ul-
timately health care delivery and primary prevention 
strategies. By combining data resources into one na-
tionwide CVD registry, we will have greater oversight 
and a greater likelihood of reducing the burden of 
disease in the population. 
 The core NCVDR will consist of data of cardio-
vascular disease patients identified starting Jan 1, 2012 
from the Norwegian Patient Registry (37) and Cause 
of Death Registry (38), with supplemental information 
from the Central Population Registry (39) (Figure 1). 
CVD patients will be identified using the relevant 
ICD-10 codes associated with CVD (40) (Table 1). 
Patients will be included in the registry if they were dis-
charged from hospital or out-patient clinics with one of 
the listed diagnostic codes (as main or secondary diag-
noses). In addition, all the deceased with any CVD-
related diagnose as the underlying or contributing 
cause of death, will be included in the registry. 
 Of note for diabetes researchers is that the ICD-10 
codes for diabetes found in ICD-10 Chapter IV regar-
ding endocrine, nutritional, and metabolic disorders 
are not used as qualifying criteria for inclusion in the  
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Figure 1.  Diagram of the Norwegian Cardiovascular 
Disease Registry (NCVDR) Components. Abbreviations: 
NPR, National Patient Registry; CDR, Cause of Death 
Registry; National Reg, National Population Registry. 
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Table 1.  Qualifying International Classification of Disease (ICD-10) Codes utilized for identifying patients for inclusion in 
the Norwegian Cardiovascular Disease Registry. 
 
ICD-10 
Chapter 
Category 
Codes Diagnoses 
I A00-B99 Certain infections and parasitic diseases 
II C38 Malignant neoplasm of heart 
II D15 Benign neoplasm of other and unspecified intrathoracic organs 
V F01 Vascular dementia  
VI G45 Transient cerebral ischeamic attacks and related syndromes 
VI G46 Vascular syndromes of brain in cerebrovascular diseases (I60-I67) 
VII H34 Retinal vascular occlusions 
IX I00-I99 Diseases of the circulatory system 
XI K55 Vascular disorders of intestine 
XIV N28 Other disorders of kidney and ureter, not elsewhere classified 
XV O10-O16 Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium 
XV O20-O29 Other maternal disorders predominantly related to pregnancy 
XV O89 Complications of anaesthesia during the puerperium 
XV O90 Complications of the puerperium, not elsewhere classified 
XV O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the 
puerperium 
XVI P00 Fetus and newborn affected by maternal conditions that may be unrelated to present pregnancy 
XVI P10 Intracranial laceration and haemorrhage due to birth injury 
XVI P25 Interstitial emphysema and related conditions originating in the perinatal period 
XVI P29 Cardiovascular disorders originating in the perinatal period 
XVI P52 Intracranial nontraumatic haemorrhage of fetus and newborn 
XVII Q20-Q28 Congenital malformations of the circulatory system 
XVIII R00-R09 Symptoms and signs involving the circulatory and respiratory systems 
XVIII R23 Other skin changes 
XVIII R55-R69 General symptoms and signs 
XVIII R90-94 Abnormal findings on diagnostic imaging and in function studies without diagnosis 
XVIII R95-R99 Ill defined and unknown causes of mortality 
XIX S00-S99 Injuries (heart and large vessels)  
XIX T80-T88 Complications of surgical and medical care, not elsewhere classified 
XX Y60-Y69 Misadventures to patients during surgical and medical care 
XX Y70-Y82 Medical devices associated with adverse incidents in diagnostic and therapeutic use 
XX Y83-Y84 Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later 
complication, without mention of misadventure at the time of the procedure 
XXI Z00-Z13 Persons encountering health services for examination and investigation 
XXI Z40-Z54 Persons encountering health services for specific procedures and health care 
XXI Z80-Z99 Persons with potential health hazards related to family and personal history and certain conditions 
influencing health status 
Source: World Health Organization, International Classification of Disease-10, Version 2010, English. 
Available at: http://apps.who.int/classifications/icd10/browse/2010/en 
 
 
 
CVD Registry. Instead, the ICD-10 codes associated 
with diabetes are to be available only among patients 
with the CVD-related qualifying diagnoses noted in 
Table 1. Many patients with diabetes will have addi-
tional CVD diagnoses when being hospitalized, and 
many CVD patients will have diabetes as a secondary 
diagnosis. 
 The NCVDR will also collect information from the 
medical quality registries for selected conditions and 
procedures, including stroke, myocardial infarction, and 
vessel surgery, and, pending approvals, coronary angio-
graphy and percutaneous coronary intervention (PCI). 
DIABETES RESEARCH OPPORTUNITIES 
 
Given the burden of CVD among diabetic patients and 
the unique challenges they pose for clinicians, the 
formation of the NCVDR provides an opportunity to 
engage in research that will ultimately improve our 
understanding and clinical care for this high-risk patient 
population. We foresee the development of research 
projects comparing the prognosis for CVD patients 
with and without diabetes. Further, we foresee future 
data linkages between the NCVDR and other data 
sources for evaluating specific questions that can not 
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Table 2.  Data sources of relevance for diabetes research in Norway. 
 
Data Source Description Ref 
Norwegian Childhood Diabetes Registry  Type 1 diabetes diagnosed before age 15 43 
The Norwegian Diabetes Registry for Adults Adults with type 1 or 2 diabetes. Not yet national in scope 44 
Other medical quality registries (e.g., Myocardial 
Infarct Registry and Stroke Registry) 
Regarding important co-morbidities 34, 35 
National Prescription Registry (NorPD) Dispensed drugs  41 
Cohort Norway (CONOR) and Regional Health 
Screening Surveys 
Population-based health screening  42 
Norwegian Cardiovascular Disease Registry (NCVDR) National Patient Registry, Cause of Death Registry, and 
National Population Registry 
32 
 
 
 
be addressed based upon the NCVDR or other data 
sources alone. For example, linkages between the 
NCVDR and the National Prescription Registry 
(NORPD) (41) could form a database for evaluating 
pharmacological treatment modalities and prognosis 
relative to the range and severity of co-morbidities of 
relevance to diabetes. We also foresee opportunities to 
link Cohort of Norway (CONOR) or the individual 
Regional Health Survey Screening study populations 
(42) with the NCVDR for prospective evaluation of 
baseline risk factors for their association with CVD 
incidence and mortality for those with and without 
diabetes. Further, future data linkages between the 
NCVDR and the Norwegian Diabetes Registry (43) pro-
vides an opportunity to evaluate CVD sequelae for this 
important patient population. The Norwegian Diabetes 
Registry contains all registered type 1 diabetes cases 
diagnosed before age 15 years identified retrospec-
tively beginning in 1973 and identified prospectively 
since 1989. Likewise, the ongoing development of a 
nationwide adult diabetes medical quality registry, 
initiated in 2006 (44), will provide important details 
regarding medical care, glycemic control, and co-
morbidities which, through data linkages with the 
NCVDR, will represent a significant resource for both 
type 1 and type 2 diabetes research in Norway. 
 Also, the data provided by other medical quality 
registries will enable a detailed evaluation of the range 
of comorbidities, and the prognosis for diabetic patients 
following vessel surgery or coronary angiography or 
PCI procedures. These are examples of the synergistic 
research opportunities that are to emerge once the 
NCVDR is operational. 
 A similar model of research in Denmark, for 
example, allowed for linking patients with nationwide 
administrative registries of dispensed prescriptions, 
hospitalizations, and cause of death. The record link-
ages enabled the evaluation of the efficacy of clopido-
grel treatment following myocardial infarction in 
which the risk reduction for diabetics was lower than 
that observed for non-diabetic patients (28). Diabetic 
patients have increased platelet activity and despite 
clopidogrel treatment have high platelet activity (45, 
46). These and other research findings speak to the 
need for identifying appropriate risk reduction strate-
gies for CVD patients with diabetes. 
 The information gleaned from such future research 
will help provide the clinical epidemiological frame-
work for improving the quality of health care delivery 
for Norway’s high-risk CVD patients with diabetes.
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